Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XmAb5485
- Development stage
- Preclinical
- Lead developer
- Xencor
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
XmAb5485 is a humanized monoclonal antibody targeting CD40, developed by Xencor for the treatment of B-cell malignancies and autoimmune diseases. It incorporates Xencor's proprietary XmAb Fc-engineering technology, which significantly increases the antibody's affinity for Fc gamma receptors (FcγR). This enhancement leads to a substantial increase in effector functions, notably a 150-fold improvement in antibody-dependent cell-mediated cytotoxicity (ADCC) compared to non-engineered versions. Preclinical studies have demonstrated its potent anti-tumor activity in models of Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
02
Targets
CD40 (Cluster of differentiation 40 receptor)FCGR2A (Low affinity immunoglobulin gamma Fc receptor II-a)FCGR2B (Fc gamma receptor IIB)
Beyond the preview
Go deeper on XmAb5485.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XmAb5485.